|
DYNC2LI1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.02480271333161E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.6924000523797E-09 |
| Normal-vs-Stage2 |
8.93940000024074E-07 |
| Normal-vs-Stage3 |
4.22489998541664E-09 |
| Normal-vs-Stage4 |
3.6903036182423E-11 |
| Stage1-vs-Stage2 |
7.373600E-01 |
| Stage1-vs-Stage3 |
1.899400E-01 |
| Stage1-vs-Stage4 |
4.277400E-03 |
| Stage2-vs-Stage3 |
5.526000E-01 |
| Stage2-vs-Stage4 |
6.472200E-02 |
| Stage3-vs-Stage4 |
1.716590E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.57316390417373E-12 |
| Normal-vs-AfricanAmerican |
8.699700E-02 |
| Normal-vs-Asian |
2.53240000003263E-06 |
| Caucasian-vs-AfricanAmerican |
4.647800E-02 |
| Caucasian-vs-Asian |
3.967400E-01 |
| AfricanAmerican-vs-Asian |
1.448950E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.22291107532646E-12 |
| Normal-vs-Female |
2.08929995526574E-09 |
| Male-vs-Female |
6.283900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.40800002160313E-09 |
| Normal-vs-Age(41-60Yrs) |
6.63190002914149E-09 |
| Normal-vs-Age(61-80Yrs) |
8.05500000033987E-09 |
| Normal-vs-Age(81-100Yrs) |
1.944460E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.987400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.822200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.076000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.909400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.183400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.930200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.890100E-02 |
| Classical-VS-Follicular |
9.667600E-02 |
| Classical-VS-Other |
9.723400E-01 |
| Classical-VS-Normal |
8.24920132203033E-11 |
| Tall-VS-Follicular |
1.958670E-03 |
| Tall-VS-Other |
2.405400E-01 |
| Tall-VS-Normal |
7.06309999376487E-09 |
| Follicular-VS-Other |
6.171200E-01 |
| Follicular-VS-Normal |
1.994120E-04 |
| Other-VS-Normal |
1.699570E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.03409996916093E-09 |
| Normal-vs-N1 |
1.35069999629422E-09 |
| N0-vs-N1 |
6.456500E-02 |
|
|
